METHOD FOR PREDICTION OF LIVER FIBROSIS DYNAMICS IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, NOT RESPONDING TO TREATMENT WITH PEGYLATED INTERFERONS AND RIBAVIRIN Russian patent published in 2017 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention is intended to predict the reliability of the liver fibrosis dynamics in patients with HCV, genotype 1, not responding to two-component antiviral therapy with pegylated interferons and ribavirin. Blood group in combination with the study of IL28B gene polymorphism is determined, at that, in 100% of cases liver fibrosis progression was observed in patients with blood group Aβ (II) and one- or two-nucleotide substitution of cytosine by thymine (C>T) in the rs 12979860 locus and one- or two-nucleotide substitution of thymine by guanine (T>G) in the rs 8099917 locus of the IL28B gene.

EFFECT: method allows selection of patients for non-interferon therapy, which eliminates the negative dynamics of liver fibrosis for this category of patients and reduces the cost of treatment.

4 tbl